Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

The bioengineering company Ossium Health has created a new program that offers deep-frozen bone marrow from deceased organ ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Acute myeloid leukemia (AML) is a malignant hematological disease originating from hematopoietic stem/progenitor cells, accounting for about 80% of acute leukemia in adults. The risk of developing ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

Positive preliminary outcomes were reported for the first leukemia patient treated with Ossium Health's organ donor bone ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...